TR200201503T2 - Heterosiklik türevler. - Google Patents

Heterosiklik türevler.

Info

Publication number
TR200201503T2
TR200201503T2 TR2002/01503T TR200201503T TR200201503T2 TR 200201503 T2 TR200201503 T2 TR 200201503T2 TR 2002/01503 T TR2002/01503 T TR 2002/01503T TR 200201503 T TR200201503 T TR 200201503T TR 200201503 T2 TR200201503 T2 TR 200201503T2
Authority
TR
Turkey
Prior art keywords
heterocyclic derivatives
antagonize
enantiomer
pyrrolidinyl
solvate
Prior art date
Application number
TR2002/01503T
Other languages
English (en)
Inventor
Orlandi Alessandra
Original Assignee
Glaxo Wellcome Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome Spa filed Critical Glaxo Wellcome Spa
Publication of TR200201503T2 publication Critical patent/TR200201503T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)

Abstract

Bu bulus,7-kloro-4(2-okso-1-fenil-3-pirrolidinilden)-1,2,3,4 tetrahidro-2- kuinolin karboksilik asit A enantiomerinin yeni bir tuzu veya bir solvatiyla, hazirlanma prosesleriyle, bunlari içeren farmasötik terkiplerle ve terapide, özellikle NMDA reseptör kompleksi üzerinde uyarici amino asitlerin etkilerini antagonize etmek üzere bir ilaç olarak kullanimiyla ilgilidir.
TR2002/01503T 1999-12-08 2000-12-07 Heterosiklik türevler. TR200201503T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9929037.1A GB9929037D0 (en) 1999-12-08 1999-12-08 Heterocyclic derivatives

Publications (1)

Publication Number Publication Date
TR200201503T2 true TR200201503T2 (tr) 2002-10-21

Family

ID=10865952

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2002/01503T TR200201503T2 (tr) 1999-12-08 2000-12-07 Heterosiklik türevler.

Country Status (30)

Country Link
US (2) US6713491B2 (tr)
EP (1) EP1237886B1 (tr)
JP (1) JP4311901B2 (tr)
KR (1) KR100788579B1 (tr)
CN (1) CN1325488C (tr)
AR (1) AR030923A1 (tr)
AT (1) ATE323691T1 (tr)
AU (1) AU769232B2 (tr)
BR (1) BR0016235A (tr)
CA (1) CA2393303C (tr)
CO (1) CO5251474A1 (tr)
CY (1) CY1106105T1 (tr)
CZ (1) CZ301052B6 (tr)
DE (1) DE60027461T2 (tr)
DK (1) DK1237886T3 (tr)
ES (1) ES2257343T3 (tr)
GB (1) GB9929037D0 (tr)
HK (1) HK1047436B (tr)
HU (1) HUP0203650A3 (tr)
IL (2) IL150010A0 (tr)
MX (1) MXPA02005802A (tr)
MY (1) MY129892A (tr)
NO (1) NO323263B1 (tr)
PL (1) PL356713A1 (tr)
PT (1) PT1237886E (tr)
TN (1) TNSN00240A1 (tr)
TR (1) TR200201503T2 (tr)
TW (1) TW524804B (tr)
WO (1) WO2001042238A1 (tr)
ZA (1) ZA200204492B (tr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4616168B2 (ja) * 2003-04-25 2011-01-19 日本ケミファ株式会社 （２ｓ，３ｓ）−３−［［（１ｓ）−１−イソブトキシメチル−３−メチルブチル］カルバモイル］オキシラン−２−カルボン酸の塩
GB0327912D0 (en) * 2003-12-02 2004-01-07 Glaxo Group Ltd Medicament
US7576216B2 (en) * 2004-07-30 2009-08-18 Abbott Laboratories Preparation of pyridonecarboxylic acid antibacterials
PT3056492T (pt) 2004-10-08 2021-12-27 Abbvie Inc Sal de meglumina e formas cristalinas do mesmo de um fármaco (delafloxacina)
ME02003B (me) * 2005-04-11 2012-12-31 Abbott Lab Farmaceutske smeše koje imaju unapređene profile rastvaranja za lekove koji su slabo rastvorljivi
BR112014009910B1 (pt) * 2011-10-25 2020-06-30 Janssen Pharmaceutica N.V. sal di-hidrato de meglumina de ácido 1-(5,6-dicloro-1h-benzo[d]imidazol-2-il)-1h-pirazol-4-carboxílico, composição farmacêuticae pomada tópica

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231102A (en) 1989-03-08 1993-07-27 Merck Sharp & Dohme, Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
US5529999A (en) 1994-03-04 1996-06-25 Eli Lilly And Company Antitumor compositions and methods of treatment
US6413959B1 (en) * 1995-04-14 2002-07-02 Boehringer Ingelheim Kg Method of treating depression with arylglycinamide derivatives
WO1997012870A1 (en) * 1995-09-29 1997-04-10 Glaxo Wellcome S.P.A. Tetrahydroquinolines as nmda antagonists
GB9617305D0 (en) 1996-08-17 1996-09-25 Glaxo Wellcome Spa Heterocyclic compounds
MY125037A (en) * 1998-06-10 2006-07-31 Glaxo Wellcome Spa 1,2,3,4 tetrahydroquinoline derivatives

Also Published As

Publication number Publication date
CO5251474A1 (es) 2003-02-28
DE60027461T2 (de) 2006-09-28
EP1237886B1 (en) 2006-04-19
CZ301052B6 (cs) 2009-10-21
NO20022682L (no) 2002-07-17
KR20020086854A (ko) 2002-11-20
US6713491B2 (en) 2004-03-30
EP1237886A1 (en) 2002-09-11
HK1047436B (zh) 2006-07-21
US20040162313A1 (en) 2004-08-19
CA2393303C (en) 2009-10-20
AR030923A1 (es) 2003-09-03
PT1237886E (pt) 2006-07-31
BR0016235A (pt) 2002-08-27
TNSN00240A1 (en) 2002-05-30
CZ20021981A3 (cs) 2003-01-15
CN1407980A (zh) 2003-04-02
WO2001042238A1 (en) 2001-06-14
KR100788579B1 (ko) 2007-12-26
ES2257343T3 (es) 2006-08-01
DK1237886T3 (da) 2006-08-14
US20030008899A1 (en) 2003-01-09
IL150010A (en) 2009-09-01
NO323263B1 (no) 2007-02-19
HUP0203650A3 (en) 2004-01-28
ATE323691T1 (de) 2006-05-15
HUP0203650A2 (hu) 2003-03-28
MY129892A (en) 2007-05-31
HK1047436A1 (en) 2003-02-21
CY1106105T1 (el) 2011-06-08
MXPA02005802A (es) 2004-08-12
NO20022682D0 (no) 2002-06-06
DE60027461D1 (de) 2006-05-24
JP4311901B2 (ja) 2009-08-12
IL150010A0 (en) 2002-12-01
CN1325488C (zh) 2007-07-11
ZA200204492B (en) 2004-06-30
US6943176B2 (en) 2005-09-13
CA2393303A1 (en) 2001-06-14
JP2003516403A (ja) 2003-05-13
TW524804B (en) 2003-03-21
AU2006001A (en) 2001-06-18
GB9929037D0 (en) 2000-02-02
PL356713A1 (en) 2004-06-28
AU769232B2 (en) 2004-01-22

Similar Documents

Publication Publication Date Title
TR200200648T2 (tr) Farmasötik özelliklere sahip yeni dikarboksilik asit türevleri.
BR0315547A (pt) Derivados de quinolina como antagonistas de crth2
TR200100137T2 (tr) Obesitenin ve başka bozuklukların tedavisinde yararlı nöropeptit Y Y5 reseptörü için ligandlar olarak N-ikameli aminotetralinler.
AP1760A (en) Platinum derivative pharmaceutical formulations.
ATE284861T1 (de) N-aralkylaminotetraline als neuropeptid-y-y5- rezeptorliganden
MY144897A (en) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
SE9904505D0 (sv) Novel compounds
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
BR0016543A (pt) Novos derivados de piperidina e piperazina
MY115638A (en) N-substituted heterocyclic derivatives, their preparation and pharmaceutical compositions containing them
RS103903A (en) Piperidine derivatives as nmda receptor antagonists
PT1086124E (pt) Ciclosporinas novas
ES2187300A1 (es) Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos.
ATE233754T1 (de) Diphenyl-piperidin derivate
EP0337136A3 (en) Piperidine derivatives in the treatment of extrapyramidal side effects associated with neuroleptic therapy
TR200201503T2 (tr) Heterosiklik türevler.
MD553G2 (ro) Derivaţi noi ai pirazolopirimidinelor, antagonişti ai receptorilor angiotensinei II, procedee de preparare a lor, compoziţii farmaceutice care le conţin
HUP0000307A2 (hu) Y Neuropeptid antagonisták és ezeket tartalmazó gyógyászati készítmények
MX9600165A (es) 3-alcoxicarbonil-tiadiazinonas, proceso para su preparacion y composiciones farmaceuticas que las contienen.
SG146685A1 (en) Dihydroporphine derivatives, processes for their preparation, and pharmaceutical compositions containing them
ATE402178T1 (de) Substituierte 5,6,6a,11b-tetrahydro-7-oxa-5-aza- benzoäcüfluoren-6-carbonsäurederivate als nmda- antagonisten
MXPA04000952A (es) Sales de derivados de acido 1,2,3-4-tetrahidro-isoquinolin-2-carboxilico.
SE9704835D0 (sv) New compound